Apolipoprotein A-I (apoA-I) is the major functional protein fraction of high-density lipoprotein. The prophylactic effect and mechanism of human apoA-I on atherosclerosis (AS) were investigated in a high-fat diet-induced AS rabbit model. The rabbits were injected with apoA-I once a week while fed high-fat diet for 20 weeks. Our results showed that apoA-I could raise the serum level of highdensity lipoprotein-cholesterol and reduce those of lipid total cholesterol, triglyceride, and lowdensity lipoprotein-cholesterol in AS rabbits. Decreased aortic plaque area and aortic injury degree were also observed by Oil Red O staining and HE staining in apoA-I-treated high-fat dietinduced AS rabbits. Further study elucidated that apoA-I could down-regulate the expression of some inflammatory mediators including intercellular adhesion molecule type 1, vascular adhesion molecule-1 (VCAM-1), monocyte chemoattractant protein-1, tumor necrosis factor-α, interleukin-6 (IL-6), and C-reactive protein in serum and aorta of AS rabbits. In addition, real-time quantitative RT-PCR analyses showed that the apoA-I infusions decreased the mRNA levels of two proinflammatory molecules, i.e. nuclear factor kappa B (NF-κB) and cyclooxygenase-2 (COX-2), in aorta of AS rabbits, which was associated with a concomitant reduction in endothelial VCAM-1 and IL-6 mRNA transcription. Together, our results support the atheroprotective and prophylactic role of apoA-I in vivo, and this activity may be correlated with its anti-inflammatory effect.
Introduction
Cardiovascular disease is the largest cause of morbidity and premature mortality globally, and its major underlying pathology is atherosclerosis (AS) that appears as an initial accumulation of lipid in the vessel wall followed by the gradual development of complex atherosclerotic plaques. The acute rupture of these plaques can trigger the usually fatal clinical event [1] . It has been reported that AS is a chronic inflammatory disorder characterized by the progressive recruitment of macrophages and T-lymphocytes to the arterial intima and further migration into the subendothelial spaces [2] . This process is associated with an increase in the plasma levels of several inflammatory markers, among them are markers of systemic inflammation produced in the liver, such as high-sensitivity C-reactive protein, cytokines like interleukin-6 (IL-6), tumor necrosis factor-α (TNF-α) and monocyte chemoattractant protein-1 (MCP-1), and cellular adhesion molecules like soluble intercellular adhesion molecule type 1 (sICAM-1), and vascular adhesion molecule-1 (VCAM-1) [2] [3] [4] [5] [6] . The levels of these circulating inflammatory molecules reflect the clinical course of AS. Controlling the expression of these molecules may provide opportunities to develop new therapeutic agents to prevent the development and progression of AS [1, 7, 8] .
There is plenty of evidence supporting the atheroprotective properties of high-density lipoprotein (HDL). An inverse relationship has been identified between the risk of developing cardiovascular disease and the plasma concentration of HDL in many studies [9, 10] . The atheroprotective activities of HDL particles are mediated by its various functions, including reverse cholesterol transport or antiinflammatory, antioxidant, and vascular protective properties [11] . However, many experimental studies suggest that it is not sufficient to protect against AS by simply raising HDL levels [12] . Attention has been focused on specific HDL subfractions and on biomarkers of HDL function as potential therapeutic targets for cardiovascular protection. A variety of HDL/apolipoprotein A-I (apoA-I)-based therapies are currently under investigation [13] [14] [15] [16] .
ApoA-I is the major protein fraction of HDL, conferring to the latter most of its pleiotropic atheroprotective function [17, 18] . The inhibition and even accelerated regression of atherosclerotic lesion have been observed in various preclinical animal studies by intravenous administration of apoA-I or reconstituted HDL particles, or overexpression of apoA-I [19] [20] [21] [22] [23] . Thus, upregulation of apoA-I level is widely considered as one of the most promising approaches in HDL-related therapies [24, 25] . Further studies have shown that apoA-I inhibits AS through participating in reverse cholesterol transport, plaque remodeling, and its anti-inflammatory, antioxidant, anti-thrombotic, and membrane protective effects [26] . To our knowledge, there is yet no report concerning the prophylactic effect of apoA-I on high-fat diet-induced AS.
In this study, we established an AS rabbit model by high-fat diet. To investigate the prophylactic effect of apoA-I, the rabbits were injected with apoA-I once a week while fed high-fat diet for 20 weeks. We observed that apoA-I could dramatically alleviate aortic plaque area and aortic injury degree, and reduce serum levels of total cholesterol (TC), triglyceride (TG), and low-density lipoprotein-cholesterol (LDL-C) in AS rabbits. In order to further explore the mechanism of apoA-I to prevent AS, we investigated the effects of apoA-I on the expression of inflammatory cytokines which play key roles in the pathogenesis of AS in aorta and serum of rabbits. In addition, since cyclooxygenase-2 (COX-2) and nuclear factor kappa B (NF-κB) were regarded as a key mediator of AS and inflammation [5, 27] , we also looked into the effects of apoA-I on the mRNA transcription levels of COX-2 and NF-κB in aorta of atherosclerotic rabbits. Our research supported the atheroprotective and prophylactic effect of apoA-I on AS in vivo.
Materials and Methods

Chemicals and reagents
Purified apoA-I used in this study was from healthy human plasma with the purity of 96% and was kindly provided by Shanghai RAAS Blood Products Co. Ltd. (Shanghai, China). The kits for assay of TC, TG, high-density lipoprotein-cholesterol (HDL-C), and LDL-C were purchased from Shanghai Rongsheng Bioengineering Company (Shanghai, China). Lipitor (atorvastatin calcium tablet) was provided by Pfizer Incorporated (New York, USA). Oil Red O powder was purchased from Jingke-Hongda Biological Technology Company (Beijing, China). All other reagents used were commercially available.
Animals
Male New Zealand white rabbits (1.8-2.0 kg body weight) were provided by Animal Experimental Center of Fudan University (Shanghai, China). There, rabbits were housed individually in metal cages with constant temperature and relative humidity (24 ± 2°C and 50%-60%, respectively). All the animals were kept under a circadian rhythm with 12 h of light and 12 h of darknesss. Water was provided at libitum. Rabbits were randomly divided into five groups: normal control group (NC), atherosclerotic model group (MD), apoA-I (20 mg/kg/w) group, apoA-I (40 mg/kg/w) group, and Lipitor group (AT) (n = 10 in each group). The rabbits in the NC group were given standard laboratory chow, and the rabbits in other groups were fed with high-fat diet (standard diet supplemented with 1.0% cholesterol, 30 g/day) and standard diet (120 g/day). The MD group was intravenously injected with 5 ml of physiological saline once a week. Doses of apoA-I and Lipitor were adjusted according to changes in body weight. ApoA-I (20 mg/kg/w) and apoA-I (40 mg/kg/w) group were intravenously injected pure human apoA-I (20 or 40 mg/kg) once a week, while AT group took atorvastatin calcium tablet orally (10 mg/kg, every day). After 20 weeks of treatment, rabbits were euthanized. Whole blood, aorta, and liver samples were collected for further examinations. Aorta and liver samples were immersed in ice-cold phosphate buffered saline (PBS). Some of them were fixed in situ with 10% of formaldehyde buffer and then embedded in paraffin, others were immediately frozen in liquid nitrogen for further analysis. Body weight of all rabbits was recorded once a week and before sacrifice to determine the body weight variations. All animal experiments were performed under the approval of the Animal Research Committee of Fudan University (Shanghai, China), and in accordance with the Guidelines of Animal Experiments from the Committee of Medical Ethics, Ministry of Health of China.
Preparation of blood serum and aorta/liver homogenates
Fasting blood samples were collected from the heart after the rabbits were euthanized. To obtain serum for further examinations, whole blood was left to stand for 30 min and then centrifuged at 1200 g for 10 min at 4°C. Segments from the aorta or liver were cut into pieces and immersed in a defined volume of physiological saline. Then, the samples were homogenized at 60 Hz for 30 s using organization homogenate machine (Jingxin Scientific company, Shanghai, China). The supernatant was obtained by centrifugation at 1500 g for 15 min at 4°C. Different concentrations (w/v) of aorta or liver homogenates were prepared for different experiments.
Analysis of serum lipids
The TC and TG in serum were measured by oxidase-peroxidase method following the manufacturer's instructions. In brief, TC or TG in serum was catalyzed by a series of enzymes to produce quinine imine. Then quinine imine produced by TC or TG was examined by spectrophotometer at 546 nm. LDL-C and HDL-C in serum were determined using commercially available kits. According to the instructions, HDL-C or LDL-C in serum could be catalyzed specifically by enzymes to form quinine imine. The concentration of HDL-C or LDL-C was obtained by measuring the absorbance of quinine imine at 546 nm.
Aortic Oil Red O staining
Thoracic aortas removed from each animal were cut open longitudinally, then fixed in 10% neutral buffered formalin-calcium chloride solution, dehydrated, and stained with Oil Red O. Atherosclerotic plaques were stained red, photographed using Canon camera. The photographs were analyzed by the Image. Pro PlusImage analysis software (Media Cybernetics Company, Bethesda, USA) was applied to calculate the ratio of plaque area.
Histopathological examination of aorta
One piece of aortic tissue was removed from the same part of each rabbit. The samples were fixed with 10% formalin solution, dehydrated, embedded in paraffin, sectioned (4-6 μm thickness) and stained with hematoxylin-eosin (HE). Optical microscopic examinations were performed with an Olympus microscope (Olympus Corporation, Japan).
Evaluation of liver lesions
Liver index and liver lipids were determined, and liver gross morphological observation and histopathological examination were performed as described before [28] .
Enzyme-linked immunosorbent assay
The serum and aorta levels of important cytokines in the inflammatory process, including ICAM-1, VCAM-1, MCP-1, TNF-α, IL-6, and C-reactive protein (CRP), were determined in 96-well plates using enzyme-linked immunosorbent assay (ELISA) kits (RND Corporation, Minneapolis, USA). Standards were diluted to the indicative concentration, and 50 μl of serum or aortic homogenate and standards combined with 50 μl of biotin was added to each well. After incubated for 60 min at 37°C, each well was washed extensively with cleaning mixture for three times. Then, 60 μl of affinity streptomycin-HRP were added. After 30 min of incubation at 37°C, each well was washed for three times, then 50 μl of substrate A and B were added. Finally, 50 μl of stop solution was added after 10 min of incubation at 37°C. The optical density was measured at 450 nm using a microplate scanning spectrophotometer (DYNEX Technologies, Chantilly, USA).
Real-time reverse transcription polymerase chain reaction
The aorta was perfused with nuclease-free PBS and total RNA was extracted from segments of aorta using Trizol reagent (Invitrogen, Carlsbad, USA) in accordance with the manufacturer's protocol. After the concentration was determined and adjusted, equal amounts (1 μg) of total RNA were reverse-transcribed into cDNA in 20 μl reaction mixture using RevertAid TM Premium First Strand Table 1 . To determine the threshold cycle (Ct) value, a two-step PCR (denaturation at 95°C for 15 s, annealing and extension at 60°C for 1 min for 40 cycles) was conducted. Expression of VCAM-1, IL-6, COX-2, and NF-κB was calculated using ΔΔCt method with GAPDH as normal reference. Reactions were carried out at least twice from independent cDNA preparations. The ratio of target gene (VCAM-1, IL-6, COX-2, and NF-κB)/GAPDH was used to represent the mRNA relative level of target gene.
Statistical analysis
The data were expressed as the mean ± SEM. Statistical analysis was performed by one-way analysis of variance for comparisons between two groups. All data were statistically analyzed by computerized statistical packages (SPSS 11.5). Differences were considered to be significant for P-values <0.05.
Results
ApoA-I had no effect on body weight and attenuated high-fat diet-induced hepatic lesions
During the experiments, most of rabbits had regular food and water intake. All rabbits gained weight gradually, and there was no significant difference between groups. At the end of 20 weeks, the weight of the animals in each group was significantly increased compared with the weight at the beginning of the experiment (P < 0.05) ( Table 2) . ApoA-I attenuated the hepatic lesions in high-fat diet-fed rabbits and the results were shown in our previous publication [28] .
ApoA-I significantly decreased aortic lesions induced by high-fat diet
In order to evaluate the effect of apoA-I on aortic lesions induced by high-fat diet in rabbits, both Oil Red O staining and HE staining were employed to observe atherosclerotic plaque area and aortic injury degree. As shown in Fig. 1A ,B, in the aorta intima of NC rabbit there were no visible atherosclerotic plaques, whereas obvious plagues were observed in other groups (red). Compared with MD group, atherosclerotic plaque area was significantly decreased by 48.32%, 54.31%, and 55.74% in apoA-I (20 mg/kg/w), apoA-I (40 mg/kg/w), and AT group (P < 0.05), respectively. High-dose apoA-I (40 mg/kg/w) was more effective than low-dose apoA-I (20 mg/kg/w) in preventing the progression of plaque. HE staining in the NC group showed that the structure of aortic vascular wall was well-defined and intact concerning intima, media, and adventitia. There was no lipid deposition under endothelium and no endotheliosis. Furthermore, the vascular smooth muscle cells (VSMCs) in the media were well organized with blue stained nucleus (Fig. 2) . In the MD group, the intimal thickness increased significantly, and the medial VSMCs arranged disorderly with increased nucleus per unit area. In addition, the histopathology of the lesion showed considerable foam cell aggregation under endothelium. Similar pathological changes were also clearly seen in apoA-I (20 mg/kg/w), apoA-I (40 mg/kg/w), and AT group, but the lesion level was attenuated as compared with that of the MD group.
All of these results manifest the atheroprotective effect of apoA-I on high-fat diet-fed AS rabbit model.
Anti-atherosclerotic effect of apoA-I may be correlated with its regulation on serum lipid levels
Serum lipid profiles were determined to address whether the antiatherosclerotic effect of apoA-I is due to the change in lipid levels. Compared with NC group, serum lipid levels increased significantly in the other groups including TC, TG, LDL-C, and HDL-C (P < 0.05). The serum levels of TC and LDL-C in apoA-I (20 and 40 mg/kg/w) groups and AT group decreased, meanwhile, the HDL-C level increased modestly when compared with MD group (Fig. 3) . Particularly, significant decrease of LDL-C and TC was observed in apoA-I (40 mg/kg/w) group and AT group (P < 0.05). These findings suggest that the antiatherosclerotic effect of apoA-I may be correlated with its regulation on serum lipid levels. ApoA-I down-regulated the levels of ICAM-1, VCAM-1, MCP-1, TNF-α, IL-6, and CRP in serum and aortic homogenate
It has been proposed that AS is an inflammatory process which involves the participation of various cytokines and acute-phase reactants, including ICAM-1, VCAM-1, MCP-1, TNF-α, IL-6, CRP and so on [29] . These inflammatory mediators could contribute to the development of AS through respective and mutual effects. Thus, pharmacotherapy aimed at inhibiting the underlying inflammatory mechanisms is considered to be a potential intervention to prevent the progression of AS [7] . Here, the anti-inflammatory activities of apoA-I were assessed by analyzing its effect on the levels of these cytokines and acute-phase reactants in serum and aorta of rabbits using ELISA. Compared with MD group, the serum levels of ICAM-1, VCAM-1, MCP-1, TNF-α, IL-6, and CRP in apoA-I (40 mg/kg/w) group rabbits decreased significantly by 35.41%, 50.97%, 32.61%, 27.15%, 28.88%, and 34.65%, respectively (P < 0.05) (Fig. 4) . Furthermore, the aortic levels of ICAM-1, VCAM-1, MCP-1, TNF-α, IL-6, and CRP in apoA-I (40 mg/kg/w) group decreased by 42.14%, 12.48%, 64.06%, 60.37%, 48.27%, and 51.78%, respectively (P < 0.05) (Fig. 5) . These results suggest that the anti-atherosclerotic effect of apoA-I may be correlated with its anti-inflammatory effect, as indicated by the down-regulation of the levels of ICAM-1, VCAM-1, MCP-1, TNF-α, IL-6, and CRP in high-fat diet-fed rabbits.
ApoA-I reduced the mRNA transcription of aortic VCAM-1, IL-6, COX-2, and NF-κB
Compelling evidence has indicated a functional link between inflammation and AS with NF-κB and COX-2 as the key mediators [5, 27] . As pro-inflammatory molecules, NF-κB and COX-2 activation lead to transcription and expression of cytokines participating in the inflammatory process [30, 31] . Therefore, the effect of apoA-I on mRNA transcription of VCAM-1 and IL-6, and possible regulatory factors COX-2 and NF-κB was investigated. Real-time quantitative RT-PCR analyses showed that the mRNA transcription of VCAM-1, IL-6, COX-2, and NF-κB decreased significantly in apoA-I groups compared with in MD group (Fig. 6) . The best effect was observed in apoA-I group receiving 40 mg/kg body weight. Compared with MD group, VCAM-1, IL-6, COX-2, and NF-κB mRNA transcription were significantly reduced by 26.16%, 48.71%, 24.55%, and 18.14%, respectively in apoA-I (40 mg/kg/w) group (P < 0.05). These results further support the relationship between the atheroprotective effect of apoA-I and its anti-inflammatory activity, as indicated by the down-regulation of mRNA transcription of the inflammatory mediators VCAM-1 and IL-6, and their upstream regulatory factors COX-2 and NF-κB in high-fat diet-fed rabbits. ApoA-I decreased the serum levels of TC and LDL-C and modestly increased the serum level of HDL-C in high-fat diet-fed rabbits Compared with NC group, serum lipid levels including TC, TG, LDL-C, and HDL-C in other groups were increased significantly. The serum levels of TC and LDL-C in apoA-I (20 and 40 mg/kg/w) groups and AT group were decreased, and HDL-C level is modestly increased when compared with MD group. *P < 0.05 vs. MD group, and **P < 0.05 vs. NC group.
Discussion
In this study, the prophylactic effect and mechanism of human apoA-I on high-fat diet-induced AS were investigated in a rabbit model. Histopathological examinations showed that AS is characterized by lipid accumulation, foam cell deposition, and atherosclerotic plaque formation in the arterial wall [32] . Epidemiological studies have shown a strong and positive correlation between the serum levels of TC, TG, and LDL-C and AS risk. Importantly, Oxidized low-density lipoprotein plays key role in the pathogenesis of AS as it causes endothelial dysfunction, accumulation of foam cells, inflammation, and proliferation of VSMC in the subintimal space [33] .
However, HDL-C shows atheroprotective activity through its reverse cholesterol transport, anti-inflammatory, and antioxidant properties [34] . In our experiments, the serum lipid levels including TC, TG, and LDL-C were found to be increased significantly after 20 weeks of high-fat diet in MD rabbits. Furthermore, the aorta samples from the MD group showed obvious atherosclerotic plaque (by Oil Red O staining), and lipid deposition and foam cell aggregation (by HE staining). All of these phenomena proved that an AS rabbit model was successfully established through high-fat diet. We also observed that infusion of apoA-I markedly reduced atherosclerotic plaque area and lesion level, and down-regulated the serum levels of TC and LDL-C as compared with the MD group. These results are in agreement with the studies by Giannarell et al. [20] who demonstrated a reduction of coronary plaque volume by infusions of apoA-I, and by Bhatt et al. [35] who reported the atheroprotective effects of apoA-I through stimulating cholesterol efflux. However, the serum levels of HDL-C did not increased significantly by apoA-I infusion. Patel et al. [36] also found that although apoA-I could not significantly increase the circulating HDL level, it could mediate a sustained inhibition of inflammation in the artery wall. They suggested that the infused apoA-I interacted with the receptor(s) on the endothelial surface prior to its incorporation into the HDL fraction, and then inhibited the key regulators of inflammation such as NF-κB via influencing intracellular signaling pathways. Our investigation manifested that apoA-I infusions decreased pro-inflammatory molecule NF-κB mRNA level, which at least in part supports the abovementioned suggestion. It is widely accepted that inflammation plays a pivotal role in the pathogenesis of AS [29] . Immune cells, as well as their effector molecules dominate and accelerate the progression of atherosclerotic lesions. Activation of inflammation can elicit acute coronary syndromes. The infiltration and retention of LDL in the arterial intima can initiate an inflammatory response in the artery wall, causing increased expression of adhesion molecules and inflammatory genes by endothelial cells. Activated endothelial cells express several kinds of leukocyte adhesion molecules, such as VCAM-1 and ICAM-1 which cause blood cells flowing in the vessel to adhere at the site of inflammation, and MCP-1, a potent recruitment factor of monocytes to atherosclerotic plaques. Activated immune cells in the plaque produce inflammatory cytokines, like TNF-α, which induce the massive production of IL-6. IL-6, in turn, stimulates the production of acutephase reactants, including CRP [37] . Collectively, these findings suggest that the inflammatory process in the atherosclerotic artery may result in increased circulating levels of inflammatory cytokines and other acute-phase reactants, which reflected the clinical course of AS.
The knowledge that AS is an inflammatory disease offers opportunities for the prophylactic and therapeutic treatment of AS. It has been reported that apoA-I can exert atheroprotective effect through anti-inflammatory properties, and the increase of apoA-I is associated with a reduced risk of major cardiovascular events [38] . Using ELISA, we further observed that apoA-I infusion reduced the levels of inflammatory markers ICAM-1, VCAM-1, MCP-1, TNF-α, IL-6, and CRP in serum and aorta of AS rabbits, especially in rabbits of apoA-I (40 mg/kg/w) group. These results elucidate that the atheroprotective benefit of apoA-I may be the result of its improved anti-inflammatory capability.
Inflammation is a complicated process characterized by the activation of pro-inflammatory molecules such as NF-κB and COX-2. These pro-inflammatory molecules can then stimulate signaling pathways and transcription of cytokines participating in the inflammatory process. NF-κB is hetero-dimeric transcription factor acting on nucleus DNA, and its activation can lead to differential gene expression, cytokines production and leukocyte recruitment [30] . COX-2 is an inducible isoform of cyclooxygenase in the conversion of arachidonic acid to prostanoids which is induced by a wide range Figure 6 . ApoA-I reduced the mRNA transcription of VCAM-1, IL-6, COX-2, and NF-κB in the aorta of high-fat diet-fed rabbits The mRNA expression of VCAM-1 (A), IL-6 (B), COX-2 (C), and NF-κB (D) decreased significantly in apoA-I groups compared with MD group. * P < 0.05 vs. MD group.
of inflammatory stimuli presenting in atherosclerotic plaques [27] . Its expression is only seen in atherosclerotic lesions, but not in normal arteries. COX-2 may promote AS by sustaining and amplifying a series of different inflammatory reactions such as propagation of the inflammatory cytokine cascade and stimulation of smooth muscle cell migration [31] . Recently, selective NF-κB and COX-2 inhibitors have attracted a keen interest in the treatment of AS and other inflammatory diseases [30, 39] . The possibility that apoA-I infusions may decrease expression of inflammatory genes in vivo was investigated in AS rabbits through real-time quantitative RT-PCR method. The results of this study demonstrated that the apoA-I infusions could reduce NF-κB and COX-2 mRNA levels, and this effect was associated with a concomitant reduction in endothelial VCAM-1 and IL-6 expression. This result is consistent with the previously reported role of NF-κB and COX-2, two pro-inflammatory mediators that regulates endothelial VCAM-1, and to some extent IL-6, expression [5, 36] .
It should be noted that low-dose of apoA-I (20 mg/kg/w) could mediate a significant inhibition of aortic lesions as compared with MD group (Fig. 1) , but had weak or no effects on serum lipids (Fig. 3) and some inflammatory mediators (Figs. 4 and 5) . There are some possibilities regarding these observations. First, apart from reverse cholesterol transport and anti-inflammation, apoA-I appears to exert its atheroprotective effect through other functions such as antioxidant or anti-thrombotic properties [11] . A previous study has suggested that apoA-I can stabilize plaque through suppressing matrix metalloproteinase-2 activation which mediates plaque rupture and subsequent thrombosis, then promotes aortic lesions [40] . Second, autoantibodies against exogeneous injection of apoA-I might be induced in vivo at the end of the experiment, which could counteract a part of the effect of apoA-I on serum lipids and inflammatory mediators. But further research is needed to confirm this possibility.
In conclusion, our data support an atheroprotective role of apoA-I in vivo, and this activity may be related to its anti-inflammatory effect. Treatment with native apoA-I may attenuate plaque inflammation through effects on pro-inflammatory mediators NF-κB and COX-2-mediated pathways. The inhibition of NF-κB and COX-2 expression can then down-regulate the level of their downstream cytokines and acute-phase reactants such as ICAM-1, VCAM-1, MCP-1, TNF-α, IL-6, and CRP. Although further studies are necessary to clarify the underlying mechanisms of these effects, our results suggest that infusion of apoA-I may be a potential prophylactic option for AS through relieving the vascular inflammation that accounts for most tissue damage in cardiovascular syndromes.
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